Fig 3.

Timing and duration of responses relative to administration of talimogene laherparepvec and ipilimumab. Data are shown for confirmed responders. Administration of talimogene laherparepvec is indicated by light blue vertical lines; the interval from the first to last ipilimumab administration is indicated in yellow; and the bar ends at the first progressive disease if there is progressive disease, otherwise, at the last tumor assessment.